Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Androgen deprivation therapy (ADT) becomes less effective over time, but additional therapies like androgen receptor blockers and androgen synthesis inhibitors may extend life and improve the ...

Investigators evaluated the effectiveness of an immunotherapy in combination with standard radiation therapy for patients with intermediate-high risk localized prostate cancer.

A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT). And, newer hormone therapies and combinations with chemotherapy can ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted ...

Background: Prostate cancer (PC) is often treated with androgen-deprivation therapy (ADT), but progression remains a challenge. Darolutamide, a next-generation androgen receptor inhibitor, may improve ...

Background: Intermittent (i) and continuous (c) androgen deprivation therapy (ADT) not only play a critical role in managing prostate cancer (PC) but also impact patient’s quality of life (QoL). This ...